Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.

Ceritinib ups hyperglycaemia risk

14 Nov 2019
One million deaths in China occur each year as a result of diabetic complications.

Ceritinib use appears to carry a significant risk of developing hyperglycaemia, a new Japan study has found.

Accessing the Japan Adverse Drug Even Report (JADER) database, researchers identified signals of hyperglycaemia and related events. They identified 7,837 such cases out of 887,636 adverse drug reactions reported in the databases. Reported odds ratios (ROR) were calculated using a two-by-two contingency table.

Of the three anaplastic lymphoma kinase inhibitors (ALKIs), only ceritinib resulted in significant RORs. There were 429 database entries that initiated ceritinib use before September 2017; four of them developed hyperglycaemia, indicating an insignificant risk (ROR, 1.06, 95 percent confidence intervals [CI], 0.39–2.83).

On the other hand, seven of 132 patients who started ceritinib medication after September 2017 showed hyperglycaemia and related events. The resulting risk estimate was significant (ROR, 6.29, 95 percent CI, 2.94–13.5).

“The insignificant ROR before September 2017 might be biased due to the limited case application and/or possible prior use of crizotinib or alectinib,” researchers explained.

A similar pattern of effect was reported when JADER datapoints with use of antidiabetes agents were excluded. Of the 545 remaining users of ceritinib, eight developed hyperglycaemia events (ROR, 2.54, 95 percent CI, 1.27–5.12).

In any of the analyses performed above, crizotinib and alectinib, both ALKIs, did not result in a significantly higher likelihood of developing hyperglycaemia.

“Clinicians including diabetologists and oncologists should emphasize vigilance for ceritinib-associated hyperglycaemia,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.